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INTRODUCTION
Immunohistochemistry (IHC) is a powerful method for local-
izing specific antigens in formalin-fixed, paraffin-embedded 
(FFPE) tissues based on antigen–antibody interaction (Taylor 
and Burns, 1974). The technique is widely used in dermatolog-
ic diagnostics and research, and its applications continue to be 
extended because of its ease of use, reliability, and versatility.
In IHC an antigen–antibody construct is visualized through 
light microscopy by means of a color signal. The advantage of 
IHC over immunofluorescence techniques is the visible mor-
phology of the tissue around the specific antigen by counter-
staining, e.g., with hematoxylin (blue). Results of stained IHC 
markers are reported semiquantitatively and have important 
diagnostic and prognostic implications, particularly for skin 
tumors, lymphoma, and the detection of infectious micro-
organisms. This article presents the key steps for performing 
IHC and describes its current use in dermatology.
HISTORY
The term “antibody” was coined by Paul Ehrlich in 1891. 
Immunofluorescence staining on frozen sections based on 
antigen–antibody interactions was presented by Coons in 
1940 (for an introduction see Odell and Cook, 2013). Taylor 
and Burns developed IHC on routinely processed FFPE tissues 
in 1974. In 1975 Köhler and Milstein presented the hybrid-
oma technique to produce monoclonal antibodies (mAbs) by 
fusing an antibody-producing B cell with a myeloma cell that 
is selected for its ability to grow in tissue culture (Köhler and 
Milstein, 1975). Prior to this, polyclonal antibodies—anti-
sera that contain molecularly different antibodies that target 
multiple epitopes with varying specificity—were used. These 
result in higher levels of nonspecific background staining than 
mAbs. The hybridoma technique enabled the use of mAbs in 
IHC, with a broad range of antigens and high staining quality.
HOW IS IMMUNOHISTOCHEMISTRY PERFORMED?
Step 1: tissue processing and epitope retrieval
For fixation, 10% neutral-buffered formalin is used for 
between 4 and 24 hours. This fixation preserves morphologic 
features but compromises antigenicity to a certain extent. It 
induces alterations in the tertiary and quaternary structures 
of proteins but does not cause irreversible reduction or total 
loss of antigenic determinants in paraffin sections. Therefore, 
the epitopes of interest remain intact (Dill and Shortle, 1991). 
Then FFPE tissue should be cut into 3- to 4-μm thin sections 
and mounted on glass slides. Enzyme digestion by trypsin or 
protease can be used to “unmask” antigens that have been 
altered by formalin fixation. The most common antigen retrieval 
technique to restore the tertiary structure is heating tissue sec-
tions in water or buffered solutions (e.g., citrate or EDTA buffer).
Step 2: antigen–antibody interaction
For the direct method, labeled monospecific antibody is 
directly applied to the tissue section (Figure 1a). The antibody 
WHAT IMMUNOHISTOCHEMISTRY DOES
•  Localizes specific antigens in formalin-fixed, 
paraffin-embedded skin based on antigen–
antibody interaction.
•  Marks antigens in three steps: processing and 
epitope retrieval in the skin, antigen–antibody 
interaction, and visualization through different 
detection systems.
•  Illustrates the result of antigen–antibody 
interactions through light microscopy by means 
of a color signal, with the advantage of visible 
morphology of the cutaneous or subcutaneous 
surrounding tissue.
•  Impacts the diagnosis and prognosis of skin tumors 
and lymphomas and the detection of infectious 
microorganisms.
•  Serves numerous purposes in dermatologic research.
LIMITATIONS
•  Not all antigens are equally preserved and 
detectable through immunohistochemistry.
•  Demanding laboratory procedure with many 
possible variables; technical pitfalls can lead to 
false-negative or false-positive results.
•  Nonstandardized methods vary between 
laboratories.
•  Less sensitive and specific than PCR-based 
molecular diagnostic methods.
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staining (higher specificity) and increased sensitivity. Double 
staining (different colors) in one tissue section can be achieved 
through a combination of two immunoenzymatic systems or 
one immunoenzymatic system with different substrates. For 
detailed overviews of IHC, see Dabbs and Thompson (2013).
QUALITY CONTROL
Quality control is essential to ensure that an IHC staining is 
sensitive and specific, reproducible, and standardized. There 
can be many pitfalls in IHC (Yaziji and Barry, 2006); there-
fore, the use of positive and negative controls in each stain-
ing run is essential. A positive control is a well-characterized 
sample that contains the antigen of interest and is stained the 
same way as the specimen to be checked. The same sample 
is used for the negative control as for the positive control. It is 
stained with the same procedure, but the primary antibody is 
replaced by nonbinding Ig from the same species.
Reasons for false-negative results include improper tissue 
fixation, processing, or pretreatment. False-positive results 
can occur through nonspecific background staining. The 
most common cause of this is ionic binding of antibodies to 
charged connective tissue elements, e.g., collagen fibers. To 
avoid this, it is recommended that the tissue be incubated 
with normal serum of the same species as the secondary 
antibody (blocking). Moreover, endogenous enzyme activ-
ity must be blocked—taking into account the fixation and 
retrieval method—to further avoid false-positive reactions. 
Undissolved precipitates of chromogen or counterstain can 
also be mistaken for a positive reaction.
Validation of IHC methodologies can be achieved by par-
ticipation in round robin tests, by staining various tissue and 
tumor types to determine sensitivity and specificity, or by 
comparing staining results of different antibodies that recog-
nize similar proteins.
is most frequently conjugated with biotin. Biotin then binds 
to labeled avidin or streptavidin. Through this second layer of 
labeling, the staining is amplified. Therefore, the development 
of these multiple-step detection methods resulted in greatly 
improved sensitivity of IHC. Thus, these multiple-step detec-
tion methods allow for detection of a wide range of antigens in 
routine diagnostic FFPE tissues. The indirect method uses two 
layers of antibodies (Figure 1b and 1c). Progression from the 
one-step direct conjugate method to the multiple-step indirect 
method greatly increased the versatility of IHC because a wide 
range of unlabeled primary antibodies could then be used.
Step 3: visualization through different detection systems
Antibody molecules cannot be seen—even under electron 
microscopy—unless they are labeled or tagged for visualiza-
tion. Labeling techniques include fluorescent compounds 
(e.g., for direct immunofluorescence) or active enzymes (for 
IHC). In IHC, enzymes are added to the tissue sections, and 
these enzymes bind to the biotin, avidin/streptavidin labeled 
antibodies; the enzymes used are horseradish peroxidase or 
calf intestine alkaline phosphatase (Figure 1a and b). Then 
chromogens are added to the sections and oxidized by horse-
radish peroxidase or alkaline phosphatase, leading to a color 
reaction. The most widely used chromogens result in red or 
brown IHC staining. The method shown in Figure 1b is the 
most widely used; however, newly developed detection sys-
tems do not rely on antibody labeling through biotin and avi-
din/streptavidin. Instead, multiple secondary antibodies and 
enzymes are linked to a polymer backbone (Figure 1c). These 
new methods have the advantage of decreased background 
Figure 1. Schematic diagram of immunohistochemical techniques.  
(a) Direct method: the antigen-specific primary antibody is biotin labeled. 
Biotin binds to avidin/streptavidin. Color visualization is achieved through 
enzymatic reaction of horseradish peroxidase/alkaline phosphatase.  
(b) Indirect method: the antigen-specific primary antibody is unlabeled. The 
secondary, biotin-labeled antibody binds to primary antibody. Visualization 
is achieved accordingly through avidin/streptavidin and peroxidase/alkaline 
phosphatase complexes. The indirect method increases versatility because 
unlabeled primary antibodies can be used. (c) Indirect method with polymer 
chain detection system. Biotin and avidin/streptavidin are replaced by a 
labeled polymer chain, allowing for increased sensitivity and specificity.
Figure 2. p16INK4a expression in human melanocytic tumors. p16INK4a 
expression was determined using immunohistochemical analysis of 20 
benign nevi. (a) Representative examples of compound nevi stained with 
p16INK4a antibody (N20; Santa Cruz Biotechnology, Santa Cruz, CA) and 
positive cells detected using Permanent Red (Dako, Glostrup, Denmark). 
Bar =  50 µm. (b) The results for 15 compound and 5 dysplastic nevi are 
represented graphically. Horizontal bars indicate the median p16INK4a 
expression values. Reprinted from Scurr et al., 2011.
© 2015 The Society for Investigative Dermatology www.jidonline.org 3
RESEARCH TECHNIQUES MADE SIMPLE  
IMMUNOHISTOCHEMISTRY IN DERMATOLOGY
IHC is possibly the most widely used technique at the 
protein level in dermatologic diagnostics. It complements 
morphologic histopathology, especially for the precise 
diagnosis of skin tumors and skin lymphoma and for the 
detection of infectious microorganisms. Protein expression 
profiles detected through IHC—on the cell surface, intra-
cellularly, and in the nucleus—enable the characteriza-
tion of cell lineage, tumor, lymphoma, and inflammatory 
cell infiltrate. Intra- and extracellular pathogens—bacteria, 
parasites, and viruses (e.g., Mycobacterium tuberculosis, 
leishmaniasis, and human herpesviruses)—can be directly 
detected. IHC also plays an important role in dermatologic 
research. The following two examples demonstrate how IHC 
is used in melanoma research.
IDENTIFICATION OF A NEW MARKER FOR MELANOMA
In addition to the identification of cell lineages, IHC can be 
used to find markers that allow for discrimination of benign 
versus malignant lesions, e.g., nevi versus malignant mela-
noma. Ideally, those markers are of prognostic value. Some 
antigens show a specific IHC staining pattern, e.g., HMB45/
MART1 expression is lost in deeper dermal parts of many 
benign nevi as a sign of cell maturation. Other markers, such 
as certain oncogenes, are overexpressed in malignant lesions. 
The p16INK4a cyclin–dependent kinase plays an important 
role in cell cycle regulation. Mutations in the coding gene 
are found in families affected by multiple melanomas. In 
Figure 3. Immunohistochemical results in melanoma for selected BRAF 
V600E mutation–positive cases by DNA analyses. Case 9, a–c; case 10, d–f; 
case 20, g–i; papillary thyroid carcinoma control, j–l. (a, d, g, and j) Scanning 
magnification, hematoxylin and eosin (H&E). (b, e, h, and k) High power, 
H&E. (c, f, i, and l) Immunohistochemical stain with the anti-B-Raf (V600E) 
antibody. Reprinted with permission from Feller et al., 2013.
1. What does IHC detect?
 A. Tissue-bound autoantibodies in fresh tissues.
 B. DNA aberrations in FFPE tissues.
 C.  Specific antigens in FFPE tissues unmasked by dif-
ferent epitope-retrieval techniques.
 D.  The presence of pathogenic RNA in fresh and 
FFPE tissues.
2.  Which of the following is a true description of the 
indirect method of IHC?
 A.  Can be used only with biotin-labeled primary 
antibodies.
 B.  Uses two layers of antibodies; the primary antibody 
is unlabeled and can be visualized through differ-
ent secondary antibody–based detection systems.
 C.  Is performed with circulating autoantibodies from 
patient serum.
 D.  Is not very versatile because all primary antibod-
ies must be labeled.
3.  What is a major advantage of antigen detection  
with IHC?
 A.  Antigen–antibody constructs are visualized 
through light microscopy by means of a color sig-
nal; the morphology of the surrounding tissue can 
be made visible by a counterstaining.
 B.  It is the most sensitive method for detection of all 
antigens.
 C.  FFPE tissue does not need to be prepared for anti-
gen detection.
 D.  It is a highly standardized and simple technique; 
there are almost no technical pitfalls.
4.  Which of the following techniques is more sensitive 
than IHC for the detection of some antigens in the 
skin?
 A. Light microscopy: hematoxylin and eosin staining.
 B. Light microscopy: special stainings.
 C. Dermatoscope.
 D. PCR-based methods.
5.  What thickness of FFPE tissue sections should be used 
for IHC?
 A. 10 µm.
 B. 10 nm.
 C. 3–4 µm.
 D. 3–4 nm.
QUESTIONS
This article has been approved for 1 hour of Category 1 CME credit.  
To take the quiz, with or without CME credit, follow the link under  
the “CME ACCREDITATION” heading.
For each question, more than one answer may be correct.
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their recent investigation, Scurr et al. (2011) found that p16 
expression was significantly decreased in dysplastic nevi 
compared to benign melanocytic nevi in IHC (Figure 2). It 
has been shown that loss of p16 is common in melanomas 
and might be an independent adverse prognostic marker in 
melanoma (Lade-Keller et al., 2014). By contrast, expression 
of p16 did not help to differentiate between Spitz nevi and 
spitzoid melanomas in another study (Mason et al., 2012). 
Therefore, IHC staining of p16 in melanocytic lesions can be 
valuable for the dermatopathologist, but its full potential role 
in melanocytic lesions warrants further investigation.
IHC FOR DETERMINING SUITABILITY OF TARGETED 
THERAPIES IN MELANOMA
Another important marker in melanoma is the protoonco-
gene BRAF that is involved in regulating cell growth. Certain 
mutations in the BRAF gene are associated with shorter pro-
gression-free survival. The advent of new drugs specifically 
targeting cells harboring a V600E mutation in the BRAF gene 
has drastically changed the treatment of end-stage mela-
noma patients. To identify melanomas that harbor V600E 
mutations in the BRAF gene, PCR-based technologies and 
direct sequencing are used, which are often time- and work-
intensive. In their recent work, Feller et al. (2013) tested a 
mutation-specific antibody against BRAFV600E in IHC and 
demonstrated that it is sensitive and specific (Figure 3), indi-
cating that IHC can be used as a simple screening tool for 
BRAFV600E in melanoma. IHC could also complement 
PCR-based technologies because it has the major advan-
tage of a visible morphology. Therefore, parts of a tumor that 
are BRAFV600E-positive could be identified, or contamina-
tion by a large number of BRAFV600E-negative cells (e.g., 
lymphocytes in a lymph node metastasis) can be excluded.
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A PowerPoint slide presentation appropriate for journal club or other 
teaching exercises is available at http://dx.doi.org/10.1038/jid.2014.541.
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